DermAI to Evaluate Human Factor of Testing
The purpose of this research is to improve how well remote patch allergy testing works and make sure they are easy and practical for people to use from home.
Conditions:
🦠 Contact Dermatitis
🗓️ Study Start (Actual) 8 May 2024
🗓️ Primary Completion (Estimated) 1 August 2024
✅ Study Completion (Estimated) 31 December 2024
👥 Enrollment (Estimated) 150
🔬 Study Type INTERVENTIONAL
📊 Phase NA
Locations:
📍 Jacksonville, Florida, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • - Willing and able to provide informed consent.

    Exclusion Criteria:

    • * Has used topical or oral steroids two weeks prior to patch testing.
    • * Currently taking immunosuppression agents or is immunocompromised due to medical condition.
    • * No sunburn or rash at site of testing.
    • * Women who are breastfeeding or pregnant.
    • * Treatment with ultraviolet (UV) light (including tanning) during the two weeks prior to visit.
    • * Subjects unable to comply with patch test study requirements including multiple return visits and activity restrictions (e.g., protecting patch test area from excess moisture due to showering).
Ages Eligible for Study: 18 Years to N/A (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 23 April 2024
  • First Submitted that Met QC Criteria 23 April 2024
  • First Posted 29 April 2024

Study Record Updates

  • Last Update Submitted that Met QC Criteria 15 May 2024
  • Last Update Posted 17 May 2024
  • Last Verified May 2024